TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* An Investigational Review Board approved, written informed consent is appropriately witnessed, signed and dated prior to any study-related activities~* Male or female subjects 18 years of age or older~* Able to read and understand English~* Enrolled and started on prophylaxis within 72 hours of arrival in Mexico~* If the subject is female, only women with non-childbearing potential or those who are not pregnant will be eligible. Urine pregnancy tests will be performed on those women who question their pregnancy status. Women on the study are required to employ a reliable method of contraception while taking medication. Forms of acceptable contraception include:~  * Double barrier method of contraception.~ * Oral birth control pills for at least two cycles before enrollment and continuing during therapy - subjects will be told they should use a barrier contraception method during the study as well.~ * Norplant inserted at least one month before enrollment.~ * An intrauterine device inserted by a qualified clinician.~ * Medroxyprogesterone acetate for a minimum of one month before study and administered for one month following study completion.~ * An approved birth control patch for at least two cycles before enrollment and continuing during therapy. OR~ * Complete abstinence from intercourse for the two weeks of medication.~Exclusion Criteria:~* Acute diarrhea (criteria for travelers' diarrhea above) within the past week~* Diarrhea developing within 24 hours of study enrollment~* In Mexico for more than 72 hours~* Receipt of one of the following classes of drugs: fluoroquinolone (any drug in class), macrolide or azalide or trimethoprim-sulfamethoxazole within the past week or during the three week study~* Receipt of other medication to decrease the occurrence of diarrhea (e.g. bismuth subsalicylate or lactobacillus preparations)~* For females, pregnancy or breast feeding during the three week study~* Receipt of antidiarrheal medication (loperamide, bismuth subsalicylate, kaopectate) within 24 hours of enrollment~* Hypersensitivity to rifaximin~* Unstable medical condition including chronic renal failure and insulin dependent diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult female lupus nephritis patients, currently having a flare of lupus nephritis and considering change or initiation of an immunosuppressive medication (current flare) or had had flare of lupus nephritis in the past and at risk for a future lupus nephritis flare (future flare)~Exclusion Criteria:~* male; lupus but no lupus nephritis; change in lupus immunosuppressive treatment already made for current flare; end stage renal disease on dialysis; renal transplant or candidate for a renal transplant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Computerized patient decision-aid (Type: EXPERIMENTAL): A computerized decision-aid showing benefits and harms of medications in words patients prefer
- Usual care (lupus pamphlet) (Type: ACTIVE_COMPARATOR): A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology \[ACR\])

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant had completed treatment in a previous study of migalastat HCl given as a monotherapy~* Male and female participant agreed to use protocol-identified acceptable contraception~* Participant was willing to provide written informed consent and authorization for use and disclosure of Personal Health Information (PHI)~Exclusion Criteria:~* Participant's last available estimated glomerular filtration rate (eGFR) in the previous study was \<30 milliliter (mL)/minute (min)/1.73 meters squared (m\^2); unless there was measured GFR available within 3 months of Baseline Visit, which was \>30 mL/min/1.73 m\^2~* Participant had undergone, or was scheduled to undergo kidney transplantation or was currently on dialysis~* Participant had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before Baseline Visit~* Participant had clinically significant unstable cardiac disease in the opinion of the investigator (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or New York Heart Association class III or IV congestive heart failure)~* Participant had a history of allergy or sensitivity to AT1001 (including excipients) or other iminosugars (for example, miglustat, miglitol)~* Participant required treatment with Glyset® (miglitol) or Zavesca® (miglustat)~* Participants with severe or unsuitable concomitant medical condition~* Participants with clinically significant abnormal laboratory value(s) and/or clinically significant electrocardiogram (ECG) findings

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Migalastat HCl 150 mg (Type: EXPERIMENTAL): Migalastat HCl 150 milligram (mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Deworming and Vitamin A (DEVTA) Prepilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Local residents~* Aged 1-5 years~* Informed written parental consent~Exclusion Criteria:~* Refusal to give consent~* prior enrollment in the study

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with angiomyolipomas and have either Tuberous Sclerosis complex or Lymphangioleiomyomatosis~* Between the gaes of 18 and 65 years~* Competency to voluntarily consent~* Clinically definite diagnosis of tuberous sclerosis or S-LAM~* Adequate contraception~* At least one angiomyolipoma of 1 cm or greater in largest diameter~Exclusion Criteria:~* Use of continuous supplemental oxygen~* Concurrent infection~* Recent surgery~* Ongoing or planned pregnancy~* Lactation~* Use of an investigational drug within the last 30 days of study entrance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe and Simvastatin in Dyslipidemia of Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus with stable antidiabetic treatment since at least three months~* Total cholesterol concentrations \>135mg/dl and/or concomitant lipid lowering therapy with HMGCoA inhibitors~* Serum creatinine ≤1.5mg/dl~* Urinary albumin excretion rate \< 200μg/min~* Written informed consent~Exclusion Criteria:~* History of myocardial infarction, stroke or hospital admission for angina within the previous 6 months~* History of percutaneous transluminal coronary angioplasty or coronary artery bypass grafting~* Clinically manifest heart failure (grade III or above according to New York Heart Association criteria)~* Poor glycemic control (HbA1C \>11%)~* Primary hyperlipidemia~* Uncontrolled thyroid diseases~* Infectious disease within 4 weeks of starting~* Acute liver disease or hepatic dysfunction~* Inflammatory muscle disease or evidence of muscle problems~* Concurrent treatment with systemic steroids, androgens, cyclosporin and other immunosuppressive drugs, fibrates, high-dose niacin or cholestyramine~* Pregnancy or lactating~* Women of childbearing potential without following a scientifically accepted form of contraception~* Life-threatening conditions or terminal concomitant diseases other than diabetes~* Specific contraindications or history of hypersensitivity to the study drugs or other statins~* Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial~* Evidence of an uncooperative attitude~* Any evidence that patient will not be able to complete the trial follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, aged 18-70 years, who have been followed as an outpatient and who have been found to require a minimum dose of prednisone treatment (in addition to high-dose inhaled steroid treatment) to prevent frequent exacerbations associated with induced sputum eosinophilia.~2. Patients will be enrolled if, at screening and baseline visits, they demonstrate sputum eosinophilia and symptoms. The symptoms may effect activity and sleep but should not, in the opinion of the treating physician, be severe enough to be of concern.~3. While FEV1 after withholding bronchodilators appropriately, before and after inhaled salbutamol (200 mg), and methacholine PC20 will be measured, these need not be abnormal since the prednisone is required for the control of eosinophilic bronchitis and any clinical consequences of this, and because the bronchitis can occur without these features of asthma.~4. On the same doses of corticosteroids for a least one-month.~Exclusion Criteria:~1. Pregnancy, breast-feeding or lack of effective contraception in females of childbearing potential or females who are postmenopausal \<1 year.~2. Baseline FEV1 before bronchodilator of 40% or less of predicted. This lower FEV1 is acceptable since chronic airflow limitation secondary to the eosinophilic bronchitis or asthma is not an exclusion criteria. Neither is current or ex-cigarette smoking providing that the best FEV1 in these patients has been \>60% predicted normal or the best FEV1/VC ratio has been \>60% in the past two years.~3. Exposure to a relevant seasonal environmental allergen, known to worsen asthma control, during the study period.~4. Respiratory tract infection in the 4-weeks before the baseline visit.~5. Clinical exacerbation requiring extra prednisone treatment in the 4-weeks before V1.~6. Other cardiac, pulmonary, renal or systemic diseases that in the investigator's opinion may interfere with the study results or compromise subject's safety.~7. Previous participation in any study using anti-monoclonal drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Adults over age 18 years of age with a life expectancy of at least 3 months~* Histologically or cytologically confirmed non-small cell lung cancer at stage IIIB (with pleural effusion), stage IV, or recurrence~* Measurable disease on cross sectional imaging at least 2 cm in longest diameter (1 cm if measured by spiral CT)~* Adequate hematologic (ANC ≥ 1500 cells/µL; Hemoglobin ≥9 g/dL; platelets ≥100,000/µL and ≤500,000/µL ), renal (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min), and hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN, AST ≤ 3 x ULN)~* D-dimer ≤ 2 x ULN~Key Exclusion Criteria:~* Small cell or mixed histology~* Known history of bleeding diathesis or coagulopathy~* Any current evidence of clinically significant bleeding defined as gross hematuria, hemoptysis, or GI bleeding~* Any history of thromboembolic events (e.g., deep vein thrombosis or pulmonary thromboembolism)~* Prior chemotherapy, immunotherapy or radiotherapy to an area of measurable disease unless disease had recurred after radiotherapy~* Radiotherapy within 2 weeks preceding Study Day 1~* Symptomatic or clinically active CNS disease or metastatic lesions~* Major surgery within 4 weeks of Study Day 1~* Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)~* Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack~* A history of any condition requiring anti-platelet therapy with the exception of general cardiovascular prophylaxis with aspirin. Anti-platelet agents are prohibited during the study.~* Requirement for chronic daily treatment with NSAIDs, anti-platelet drugs, or steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Oxytocin on Approach-avoidance Tendencies to Social and Non-social Stimuli

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* right-handed~* male~* age between 18 and 35~* Normal or adjusted-to-normal vision (with lenses only)~* Dutch as mother tongue~Exclusion Criteria:~* female~* age below 18 or above 35~* neurological or psychiatric condition (e.g. epilepsy, stroke, concussion), (e.g. anxiety disorder, depression)~* use of psychotropic medication (e.g. anxiolytics, antidepressants)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Oxytocin (Type: EXPERIMENTAL): Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
- Placebo (Type: PLACEBO_COMPARATOR): Saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Training Effects on Metabolic Syndrome: Interactions With Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metabolic syndrome patients diagnosed according to the International diabetes federation consensus of 2009 (Alberti, et al., Circulation).~* 18-65 years old~Exclusion Criteria:~Cardiovascular disease or musculo-skeletal that prevents them from being able to perform intense exercise.~* Respiratory failure~* Patient ends~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PLACEBO FIRST THEN MEDICATED (Type: EXPERIMENTAL): Subjects first receive the PLACEBO tablet during 72 hours (full withdrawal). After a week of taking again their medication (MEDICATION TRIAL), they will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
- MEDICATED FIRST THEN PLACEBO (Type: EXPERIMENTAL): Subjects first receive their antihypertensive MEDICATION tablet (habitual dose prescribed by their primary care doctors). After a week they will take a PLACEBO tablet for 72 hours and will be tested again. This procedure will be repeated before and after 4 months of aerobic training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient with a diagnosis of fibromyalgia according to the 1990 American College of Rheumatology (ACR) criteria~Exclusion Criteria:~* psychiatric illness~* depression of generalised anxiety disorder~* suicidal risk~* substance abuse~* active cardiac disease~* pulmonary dysfunction~* liver disease~* renal impairment~* autoimmune disease~* chronic inflammatory rheumatoid disease~* current systemic infection~* epileptic~* active cancer~* sleep apnea~* active peptic ulcer~* inflammatory bowel disease~* unstable endocrine disease~* for men : prostatic enlargement of genito-urinary disorders~* for women : pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Minalcipran (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Femoral Triangle and Adductor Canal Blocks Versus Femoral Nerve Block for Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing primary unilateral total knee arthroplasty under the spinal anesthesia.~* Age 18 - 90 years.~* Patients conformed to American Society of Anesthesiologists (ASA) physical status I-III in preoperative assessment.~* Ability to follow the study protocol.~Exclusion Criteria:~* Inability or refusal to follow the study protocol.~* American Society of Anesthesiologists (ASA) physical status classification of IV or higher.~* Coagulopathy.~* Pre-existing lower extremity neuromuscular disorders.~* Local infection over the injection site.~* Allergy or contraindications to the drugs used in the study (local anesthetics, NSAIDs, opioids).~* Chronic opioid use.~* Other type of anesthesia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Femoral Nerve Block (Type: ACTIVE_COMPARATOR): The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
- Femoral Triangle & Adductor Canal Blocks (Type: ACTIVE_COMPARATOR): These two blocks will be performed together.~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder.~* Patient's current depressive episode must be at least 12 weeks in duration~* Patient must have a parent or caregiver who must agree to accompany the patient to all clinic visits.~Exclusion Criteria:~* Patients who currently meet DSM-IV criteria for:~  1. attention deficit-hyperactivity disorder~ 2. obsessive-compulsive disorder~ 3. posttraumatic stress disorder~ 4. bipolar disorder~ 5. pervasive developmental disorder~ 6. mental retardation~ 7. conduct disorder~ 8. oppositional defiant disorder~* Patients who are considered a suicide risk (have active suicidal ideation), who have made a suicide attempt, or who have ever been hospitalized because of a suicide attempt.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): Escitalopram 10mg once daily for three weeks, 10-20mg once daily for up to the remaining 5 weeks
- 2 (Type: PLACEBO_COMPARATOR): Placebo once daily for up to 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete